Julian Sevilla

List of Publications by Year
in descending order

111 papers	2,982 citations	159585 30 h-index	197818 49 g-index
127 all docs	127 docs citations	127 times ranked	4144 citing authors

#	Article	IF	Citations
1	Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (<scp>PKD</scp>)?: Toward an expanded definition of severe <scp>PKD</scp>. American Journal of Hematology, 2022, 97, .	4.1	3
2	Letter to the Editor: Hematopoietic Stem and Progenitor Cell Mobilization and Collection for Patients Diagnosed with Osteopetrosis and Hurler Syndrome. Human Gene Therapy, 2022, 33, 213-214.	2.7	0
3	Mobilization with highâ€dose granulocyte colonyâ€stimulating factor alone at 12â€‰Î¼g/kg twice a day in highâ€risk pediatric patients: A retrospective analysis of the experience in a single center. Journal of Clinical Apheresis, 2022, 37, 420-429.	1.3	1
4	Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia. Journal of Clinical Investigation, 2022, 132, .	8.2	2
5	Plerixaforâ€based mobilization in pediatric healthy donors with unfavorable donor/recipient body weight ratio resulted in a better <scp>CD34</scp>⁺ collection yield: A retrospective analysis. Journal of Clinical Apheresis, 2021, 36, 78-86.	1.3	3
6	Variables related to chronic immune thrombocytopenia: experience from a single center and comparison to a meta-analysis. European Journal of Pediatrics, 2021, 180, 2075-2081.	2.7	3
7	Haploâ€identical or mismatched unrelated donor hematopoietic cell transplantation for <scp>Fanconi</scp> anemia: Results from the <scp>Severe Aplastic Anemia Working Party</scp> of the <scp>EBMT</scp>. American Journal of Hematology, 2021, 96, 571-579.	4.1	14
8	A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline. Leukemia, 2021, 35, 3295-3298.	7.2	2
9	Natural gene therapy by reverse mosaicism leads to improved hematology in <scp>Fanconi</scp> anemia patients. American Journal of Hematology, 2021, 96, 989-999.	4.1	13
10	Graft failure after â€œex-vivoâ€•T-cell depleted haploidentical transplantation in pediatric patients with high-risk hematological malignancies. A risk factors and outcomes analysis. Leukemia and Lymphoma, 2021, 62, 1-8.	1.3	3
11	Management of primary immune thrombocytopenia. A comparison between two historical cohorts. Anales De PediatrÃa (English Edition), 2021, 95, 86-92.	0.2	0
12	Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes. Molecular Therapy - Methods and Clinical Development, 2021, 22, 66-75.	4.1	10
13	Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Interim Results of a Global Phase 1 Study for Adult and Pediatric Patients. Blood, 2021, 138, 563-563.	1.4	4
14	Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. New England Journal of Medicine, 2020, 382, 1811-1822.	27.0	320
15	Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC). Bone Marrow Transplantation, 2020, 55, 1744-1753.	2.4	12
16	Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. Journal of Medical Genetics, 2020, 57, 258-268.	3.2	18
17	Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. Nature Medicine, 2019, 25, 1396-1401.	30.7	117
18	NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia. Cell Stem Cell, 2019, 25, 607-621.e7.	11.1	64

#	Article	IF	Citations
19	Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency. PLoS ONE, 2019, 14, e0216674.	2.5	19
20	Vox Sanguinis International Forum on paediatric indications for blood component transfusion. Vox Sanguinis, 2019, 114, e36-e90.	1.5	0
21	Genetic analyses of aplastic anemia and idiopathic pulmonary fibrosis patients with short telomeres, possible implication of DNA-repair genes. Orphanet Journal of Rare Diseases, 2019, 14, 82.	2.7	21
22	Haploidentical Stem Cell Transplantation in Children With Hematological Malignancies Using Î±Î²+ T-Cell Receptor and CD19+ Cell Depleted Grafts: High CD56dim/CD56bright NK Cell Ratio Early Following Transplantation Is Associated With Lower Relapse Incidence and Better Outcome. Frontiers in Immunology, 2019, 10, 2504.	4.8	13
23	Leukocyte adhesion deficiency-I: A comprehensive review of all published cases. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1418-1420.e10.	3.8	85
24	Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency. Haematologica, 2018, 103, e82-e86.	3.5	42
25	Osmotic gradient ektacytometry: A valuable screening test for hereditary spherocytosis and other red blood cell membrane disorders. International Journal of Laboratory Hematology, 2018, 40, 94-102.	1.3	67
26	Protocolo diagnÃ³stico y tratamiento de la anemia microcÃ‡tica en el adolescente. Medicine, 2018, 12, 3613-3618.	0.0	0
27	Anemias raras y fallos medulares hereditarios. Arbor, 2018, 194, 463.	0.3	2
28	Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. British Journal of Haematology, 2018, 183, 110-118.	2.5	53
29	DÃ©ficit de piruvato cinasa eritrocitaria en EspaÃ±a: estudio de 15 casos. Medicina ClÃnica, 2017, 148, 23-27.	0.6	10
30	Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: Faster immune reconstitution using younger donors. Leukemia Research, 2017, 57, 60-64.	0.8	33
31	Therapeutic gene editing in <scp>CD</scp> 34 ⁺ hematopoietic progenitors from Fanconi anemia patients. EMBO Molecular Medicine, 2017, 9, 1574-1588.	6.9	54
32	Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients. Blood, 2017, 130, 1535-1542.	1.4	42
33	Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia. Blood Advances, 2017, 1, 319-329.	5.2	18
34	Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia. Current Gene Therapy, 2017, 16, 338-348.	2.0	31
35	IgAâ€Mediated Autoimmune Hemolytic Anemia: A Clinical Conundrum. Pediatric Blood and Cancer, 2016, 63, 754-754.	1.5	2
36	Hemiparesis in an Adolescent With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2016, 38, 63-64.	0.6	1

#	Article	IF	Citations
37	Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts. Bone Marrow Transplantation, 2016, 51, 1211-1216.	2.4	29
38	Immunomagnetic T Cell Depletion: an Analysis of Variables Affecting Final Cell Yield. Clinical Laboratory, 2016, 62, 1243-1248.	0.5	1
39	Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells. Stem Cell Reports, 2015, 5, 1053-1066.	4.8	32
40	Pyruvate kinase deficiency and severe congenital hemolytic anemia in a double heterozygous patient with paternal transmission of an early germâ€line de novo mutation. American Journal of Hematology, 2015, 90, E217-9.	4.1	5
41	Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematology,the, 2015, 2, e315-e325.	4.6	146
42	A phase I/II trial of interleukin-15â€“stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy, 2015, 17, 1594-1603.	0.7	69
43	Hb Cibeles [Î±2 CD25(B6) (GlyÂâ†'ÂAsp)]: a novel alpha chain variant causing alpha-thalassemia. International Journal of Hematology, 2014, 100, 599-601.	1.6	3
44	AfÃ©resis en PediatrÃa. Anales De Pediatria Continuada, 2014, 12, 256-259.	0.1	0
45	Outcome and Prognostic Factors for Pediatric Patients Receiving an Haploidentical Transplantation Using CD3/CD19 Depleted Grafts. Biology of Blood and Marrow Transplantation, 2014, 20, S33.	2.0	0
46	Defining â€œpoor mobilizerâ€•in pediatric patients who need an autologous peripheral blood progenitor cell transplantation. Cytotherapy, 2013, 15, 132-137.	0.7	14
47	Using Rheopheresis for stem cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). Transfusion and Apheresis Science, 2013, 49, 234-237.	1.0	2
48	DiagnÃ³stico y tratamiento de la trombocitemia esencial en la edad pediÃ¡trica. , 2013, , 27-33.		0
49	Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia. Bone Marrow Transplantation, 2012, 47, 1419-1427.	2.4	37
50	Priming of Hematopoietic Progenitor Cells by Plerixafor and Filgrastim in Children With Previous Failure of Mobilization With Chemotherapy and/or Cytokine Treatment. Journal of Pediatric Hematology/Oncology, 2012, 34, 146-150.	0.6	21
51	Varicella zoster central nervous system vasculitis after allogeneic hematopoietic stem cell transplant successfully treated with cyclophosphamide. Transplant Infectious Disease, 2012, 14, E107-10.	1.7	2
52	Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Experimental Hematology, 2012, 40, 882-891.e1.	0.4	43
53	High resolution melting analysis for the identification of novel mutations in DKC1 and TERT genes in patients with dyskeratosis congenita. Blood Cells, Molecules, and Diseases, 2012, 49, 140-146.	1.4	21
54	Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood, 2011, 117, 3759-3769.	1.4	108

#	Article	IF	Citations
55	Pulmonary Glial Heterotopia in a Child Diagnosed With Fanconi Anemia and Epilepsy. Journal of Pediatric Hematology/Oncology, 2011, 33, 462-464.	0.6	3
56	Allogeneic hematopoietic transplantation using haploidentical donor vs. unrelated cord blood donor in pediatric patients: a single-center retrospective study. European Journal of Haematology, 2011, 87, 46-53.	2.2	29
57	Chromosome fragility in patients with Fanconi anaemia: diagnostic implications and clinical impact. Journal of Medical Genetics, 2011, 48, 242-250.	3.2	51
58	Stem Cell Gene Therapy for Fanconi Anemia: Report from the 1st International Fanconi Anemia Gene Therapy Working Group Meeting. Molecular Therapy, 2011, 19, 1193-1198.	8.2	45
59	Graft Manipulation and Reduced-intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation From Mismatched Unrelated and Mismatched/Haploidentical Related Donors in Pediatric Leukemia Patients. Journal of Pediatric Hematology/Oncology, 2010, 32, e85-e90.	0.6	34
60	Analysis of Clinical Outcome and Survival in Pediatric Patients Undergoing Extracorporeal Photopheresis for the Treatment of Steroid-refractory GVHD. Journal of Pediatric Hematology/Oncology, 2010, 32, 589-593.	0.6	24
61	HIGH-DOSE BUSULFAN AND MELPHALAN AS CONDITIONING REGIMEN FOR AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION IN HIGH-RISK EWING SARCOMA PATIENTS: A Long-Term Follow-Up Single-Center Study. Pediatric Hematology and Oncology, 2010, 27, 272-282.	0.8	14
62	Compassionate Use Study of Caspofungin in Children with Proven or Suspected Invasive Mycosis or Persistent Febrile Neutropenia. Journal of Chemotherapy, 2009, 21, 229-231.	1.5	4
63	Lentiviral-mediated Genetic Correction of Hematopoietic and Mesenchymal Progenitor Cells From Fanconi Anemia Patients. Molecular Therapy, 2009, 17, 1083-1092.	8.2	44
64	ALLOGENEIC CORD BLOOD TRANSPLANTATION IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES: A Long-Term Follow-Up Single-Center Study. Pediatric Hematology and Oncology, 2009, 26, 165-174.	0.8	12
65	Intrathecal liposomal cytarabine in children under 4Âyears with malignant brain tumors. Journal of Neuro-Oncology, 2009, 95, 65-69.	2.9	22
66	KIRâ€“HLA receptorâ€ligand mismatch associated with a graftâ€versusâ€tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatric Blood and Cancer, 2009, 53, 120-124.	1.5	64
67	Peripheral blood progenitor cell collection adverse events for childhood allogeneic donors: variables related to the collection and safety profile. British Journal of Haematology, 2009, 144, 909-916.	2.5	31
68	Increasing Incidence of Invasive Aspergillosis in Pediatric Hematology Oncology Patients Over the Last Decade. Journal of Pediatric Hematology/Oncology, 2009, 31, 642-646.	0.6	54
69	Dyspnea as the first manifestation of primary pancreatic lymphoma. Pediatric Blood and Cancer, 2008, 50, 434-434.	1.5	4
70	Primary gastrointestinal aspergillosis after autologous peripheral blood progenitor cell transplantation: an unusual presentation of invasive aspergillosis. Transplant Infectious Disease, 2008, 10, 193-196.	1.7	19
71	Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLAâ€matched allogeneic stem cell transplantation in childhood leukaemia patients. British Journal of Haematology, 2008, 140, 340-343.	2.5	10
72	Extracorporeal photochemotherapy for steroid-refractory graft-versus-host disease in low-weight pediatric patients. Immunomodulatory effects and clinical outcome. Haematologica, 2008, 93, 1278-1280.	3.5	26

#	Article	IF	Citations
73	A comprehensive strategy for the subtyping of patients with Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network. Journal of Medical Genetics, 2007, 44, 241-249.	3.2	47
74	Early Acute Myeloblastic Leukemia Treatment for Childhood Myelodysplastic Syndrome With t(3;5) (NPM/MLF1). Journal of Pediatric Hematology/Oncology, 2007, 29, 839-840.	0.6	3
75	PBSC collection in extremely low weight infants: a single-center experience. Cytotherapy, 2007, 9, 356-361.	0.7	11
76	Extramedullary acute lymphoblastic leukaemia in childhood. European Journal of Haematology, 2007, 79, 182-182.	2.2	0
77	Hemoptisis fatal secundaria a aspergilosis pulmonar invasiva en una paciente con leucemia mieloblÃ¡stica aguda. Anales De PediatrÃa, 2007, 67, 278-279.	0.2	0
78	A Simplified Approach to Improve the Efficiency and Safety ofEx VivoHematopoietic Gene Therapy in Fanconi Anemia Patients. Human Gene Therapy, 2006, 17, 245-250.	2.7	18
79	Transient donor cell-derived myelodysplastic syndrome with monosomy 7 after unrelated cord blood transplantation. European Journal of Haematology, 2006, 77, 259-263.	2.2	34
80	Risk Score for Pediatric Intensive Care Unit Admission in Children Undergoing Hematopoietic Stem Cell Transplantation and Analysis of Predictive Factors for Survival. Journal of Pediatric Hematology/Oncology, 2005, 27, 526-531.	0.6	31
81	Hematopoietic transplantation for bone marrow failure syndromes and thalassemia. Bone Marrow Transplantation, 2005, 35, S17-S21.	2.4	11
82	High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. Journal of Neuro-Oncology, 2005, 71, 33-38.	2.9	80
83	Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results. Bone Marrow Transplantation, 2004, 33, 675-690.	2.4	71
84	Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome. Bone Marrow Transplantation, 2004, 34, 1051-1055.	2.4	20
85	A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. Bone Marrow Transplantation, 2004, 34, 1077-1081.	2.4	14
86	High-dose Chemotherapy With Autologous Stem Cell Rescue as First Line of Treatment in Young Children with Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumors. Journal of Neuro-Oncology, 2004, 67, 101-106.	2.9	30
87	Risks and methods for peripheral blood progenitor cell collection in small children. Transfusion and Apheresis Science, 2004, 31, 221-231.	1.0	14
88	Fatal Hepatic Failure Secondary to Acute Herpes Simplex Virus Infection. Journal of Pediatric Hematology/Oncology, 2004, 26, 686-688.	0.6	21
89	Engraftment Syndrome Emerges as the Main Cause of Transplant-Related Mortality in Pediatric Patients Receiving Autologous Peripheral Blood Progenitor Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2004, 26, 492-496.	0.6	15
90	Successful Treatment of Invasive Aspergillosis With Oral Voriconazole Following Intravenous Liposomal Amphotericin in a Child With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2004, 26, 117-119.	0.6	5

#	Article	IF	Citations
91	Chemotherapy-Related Secondary Acute Myeloid Leukemia in Patients Diagnosed With Osteosarcoma. Journal of Pediatric Hematology/Oncology, 2004, 26, 454-456.	0.6	12
92	Leucemia aguda en pacientes con sÃndrome de Down. Anales De PediatrÃa, 2004, 61, 515-519.	0.2	1
93	Severe systemic autoimmune disease associated with Epstein-Barr virus infection. Journal of Pediatric Hematology/Oncology, 2004, 26, 831-3.	0.6	6
94	Trasplante autÃ³logo con progenitores hematopoyÃ©ticos de sangre perifÃ©rica en niÃ±os con tumores del sistema nervioso central de alto riesgo. Anales De PediatrÃa, 2004, 61, 8-15.	0.2	1
95	Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT). Annals of Hematology, 2003, 82, 649-653.	1.8	32
96	Large volume leukapheresis in small children: safety profile and variables affecting peripheral blood progenitor cell collection. Bone Marrow Transplantation, 2003, 31, 263-267.	2.4	24
97	Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation. Haematologica, 2003, 88, 919-22.	3.5	25
98	Peripheral Blood Progenitor Cell Collection in Low-Weight Children. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 633-642.	1.8	13
99	Early onset of acute immune-mediated lung injury in a child undergoing allogeneic peripheral blood transplantation. American Journal of Hematology, 2002, 69, 56-58.	4.1	5
100	Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation. Annals of Hematology, 2002, 81, 11-15.	1.8	27
101	Malignant atrophic papulosis in an infant. British Journal of Dermatology, 2002, 146, 916-918.	1.5	32
102	Engraftment syndrome in children undergoing autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplantation, 2002, 30, 355-358.	2.4	27
103	Granulocyte colony-stimulating factor alone at 12 Î¼g/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients. Bone Marrow Transplantation, 2002, 30, 417-420.	2.4	30
104	Clinical and economic evaluation of using granulocyte colony-stimulating factor after autologous peripheral blood progenitor cell transplantation in children. Haematologica, 2002, 87, 105-6.	3.5	5
105	Predicting factors for admission to an intensive care unit and clinical outcome in pediatric patients receiving hematopoietic stem cell transplantation. Haematologica, 2002, 87, 292-8.	3.5	41
106	Autologous peripheral blood stem cell transplant in patients previously diagnosed with invasive aspergillosis. Annals of Hematology, 2001, 80, 456-459.	1.8	17
107	Acute autoimmune hemolytic anemia following unrelated cord blood transplantation as an early manifestation of chronic graft-versus-host disease. Bone Marrow Transplantation, 2001, 28, 89-92.	2.4	26
108	Therapeutic embolization and surgical excision of haemophilic pseudotumour. Haemophilia, 1999, 5, 360-363.	2.1	45

#	Article	IF	Citations
109	Successful Treatment of Trichosporon beigelii Pneumonia with Itraconazole. Clinical Infectious Diseases, 1998, 26, 999-1000.	5.8	13
110	NHEJ-Mediated Gene Editing: An Efficient Approach to Correct Mutations in Hematopoietic Stem and Progenitor Cells from Patients with Fanconi Anemia. SSRN Electronic Journal, 0, , .	0.4	0
111	T-Cell Depleted Haploidentical Transplantation in Children With Hematological Malignancies: A Comparison Between CD3+/CD19+ and TCRÎ±Î²+/CD19+ Depletion Platforms. Frontiers in Oncology, 0, 12, .	2.8	1